The available prostate-specific antigen (PSA)-based diagnostic and target-based therapeutic strategies approaches have come up with various false positives and off-target side effects in medical diagnosis and therapeutics of PCa 12. The gene discussed is KLK3; the disease is posterior cortical atrophy.